CoINcIDE: A framework for discovery of patient subtypes across multiple datasets

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Planey, Catherine R ^a   Gevaert, Olivier ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; DATA COLLECTION METHOD; GENE CLUSTER; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DATABASE; HUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; ALGORITHM; BIOLOGY; BREAST NEOPLASMS; CLUSTER ANALYSIS; COMPUTER SIMULATION; FEMALE; GENE EXPRESSION PROFILING; GENETICS; INFORMATION PROCESSING; OVARIAN NEOPLASMS; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SOFTWARE;

ALGORITHMS; BREAST NEOPLASMS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATASETS AS TOPIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; ROC CURVE; SOFTWARE;

EID: 84960085169     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0281-4     Document Type: Article

References (38)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
2. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533-40.
3. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160-7.
4. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103-9.
5. Kozak KR, Moody JS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neuro Oncol. 2009;11:833-41.
6. Park PJ. Methods of Microarray Data Analysis IV Chapter 2: Gene Expression Data and Survival Analysis. Amsterdam: Springer; 2005.
7. Leek JT, Peng RD. Opinion: Reproducible research can still be wrong: Adopting a prevention approach: Fig. 1. Proc Natl Acad Sci. 2015;112:1645-6.
8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.
9. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118-27.
10. Hedges LV. Distribution theory for Glass's estimator of effect size and related estimators. J Educ Behav Stat. 1981;6:107-28.
11. Khatri P, Roedder S, Kimura N, De Vusser K, Morgan AA, Gong Y, et al. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. J Exp Med. 2013;210:2205-21.
12. Monti S, Tamayo P, Mesirov J, Golub T. Consensus Clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn. 2003;52:91-118.
13. Strehl A, Ghosh J. Cluster ensembles - a knowledge reuse framework for combining multiple partitions. J Mach Learn Res. 2002;3:583-617.
14. Langfelder P, Horvath S. Eigengene networks for studying the relationships between co-expression modules. BMC Syst Biol. 2007;1:54.
15. Lee S, Shankar M, Park B. Clustering providers across disparate healthcare datasets using a path-based pseudo similarity measure. In: Workshop on data science for social good. 2014.
16. Kapp AV, Tibshirani R. Are clusters found in one dataset present in another dataset? Biostatistics. 2007;8:9-31.
17. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford). 2013;2013:bat013.
18. Edgar R, Barrett T. NCBI GEO standards and services for microarray data. Nat Biotechnol. 2006;24:1471-2.
19. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18:4465-72.
20. Hartigan J. Clustering Algorithms. Chichester: Wiley; 1975.
21. Şenbabaoğlu Y, Michailidis G, Li JZ. Critical limitations of consensus clustering in class discovery. Sci Rep. 2014;4:6207.
22. Girvan M, Newman MEJ. Community structure in social and biological networks. Proc Natl Acad Sci U S A. 2002;99:7821-6.
23. Csardi G, Nepusz T. The igraph software package for complex network research. Inter J 2006, Complex Sy:1695.
24. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
25. Ebbert M, Bastien R, Rowe L, Miller P, Anderson D, Boucher K, et al. PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte laboratory developed test. In 2011 ASCO Annual Meeting; 2011.
26. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-23.
27. PAM50 centroids file. UNC Genome Browser. https://genome.unc.edu/pubsup/breastGEO/pam50_centroids.txt. Accessed 06 Jun 2015.
28. Waldron L and Riester M. HGNChelper: Handy Functions for Working with HGNC Gene Symbols and Affymetrix Probeset Identifiers. http://cran.r-project.org/package=HGNChelper. 2014.
29. U.S. Product Data Sheet: The Prosigna Breast Cancer Prognostic Gene Signature. http://prosigna.com/docs/Prosigna_Product_Data_Sheet_US.pdf. Accessed 20 Dec 2015.
30. Planey CR, Butte AJ. Database integration of 4923 publicly-available samples of breast cancer molecular and clinical data. AMIA Jt Summits Transl Sci Proc AMIA Summit Transl Sci. 2013;2013:138-42.
31. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1:727-30.
32. Bastien RRL, Rodríguez-Lescure Á, Ebbert MTW, Prat A, Munárriz B, Rowe L, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012;5:44.
33. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
34. Waldron L, Riester M, Birrer M. Molecular subtypes of high-grade serous ovarian cancer: the holy grail? J Natl Cancer Inst. 2014;106:dju297.
35. Barlin JN, Jelinic P, Olvera N, Bogomolniy F, Bisogna M, Dao F, et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol Oncol. 2013;128:512-7.
36. Varma R, Hector S, Greco WR, Clark K, Hawthorn L, Porter C, et al. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol. 2007;59:711-23.
37. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-15.
38. The Broad Institute. Broad Institute GDAC Firehose Data Portal. http://gdac.broadinstitute.org/ (accessed 20 Dec 2015).